Hsa_circ_0093741 Competes with FRS2 for MiR-562 Binding Sites to Promote Nephroblastoma Progression

Overview

Journal Histol Histopathol

Specialties Anatomy & Histology
Pathology

Date 2022 Oct 26

PMID 36286392

Authors

Jiang Yong

Jun He

Feng Ning

Affiliations

Soon will be listed here.

Abstract

Background: Circular RNA (circRNA) has been shown to play an essential role in cancer progression, including nephroblastoma. Hsa_circ_0093741 was discovered to be highly expressed in nephroblastoma. However, its function and mechanism in nephroblastoma development are still vague.

Methods: The expression levels of hsa_circ_0093741, miR-562 and FRS2 (Fibroblast Growth Factor Receptor Substrate 2) were detected using western blotting and quantitative real-time polymerase chain reaction. Functional experiments were performed by using cell counting kit-8, colony formation, 5-ethynyl-2'-deoxyuridine (EdU), transwell, scratch assays in vitro and animal experiments in vivo. The interaction analysis was conducted using dual-luciferase reporter assay and RIP assay.

Results: Hsa_circ_0093741 was highly expressed in nephroblastoma tissues and cells. Functionally, hsa_circ_0093741 silencing significantly suppressed the growth, invasion, and migration of nephroblastoma cells in vitro. MiR-562 was decreased in nephroblastoma, and was validated to be a target of hsa_circ_0093741. Inhibition of miR-562 reversed the anticancer functions of hsa_circ_0093741 silencing on nephroblastoma cells. FRS2 expression was increased in nephroblastoma and served as a target of miR-562, moreover, FRS2 overexpression attenuated the inhibitory functions of miR-562 on the nephroblastoma cell malignant phenotypes mentioned above. Pre-clinically, lentivirus-mediated hsa_circ_0093741 silencing also impeded nephroblastoma tumor growth and metastasis in vivo.

Conclusion: Knockdown of hsa_circ_0093741 suppresses nephroblastoma cell growth, migration and invasion by regulating the miR-562/FRS2 axis, suggesting the potential involvement of hsa_circ_0093741 in nephroblastoma progression.

References

Apoznanski W, Sawicz-Birkowska K, Palczewski M, Szydelko T . Extrarenal nephroblastoma. Cent European J Urol. 2015; 68(2):153-6. PMC: 4526617. DOI: 10.5173/ceju.2015.571. View

Bazzaz N, Nouraee N, Zare-Mirzaie A, Shahali M, Mowla S, Vasei M . MiR-21 Expression in Wilms' Tumor. Iran J Pathol. 2019; 13(4):422-428. PMC: 6358566. View

Cao J, Huang Z, Ou S, Wen F, Yang G, Miao Q . circ0093740 Promotes Tumor Growth and Metastasis by Sponging miR-136/145 and Upregulating DNMT3A in Wilms Tumor. Front Oncol. 2021; 11:647352. PMC: 8217636. DOI: 10.3389/fonc.2021.647352. View

Chen R, Liu H, Yang L, Kang F, Xin L, Huang L . Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS. Eur Rev Med Pharmacol Sci. 2019; 23(20):8771-8778. DOI: 10.26355/eurrev_201910_19271. View

Chen Y, Lei Y, Lin J, Huang Y, Zhang J, Chen K . The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer. Onco Targets Ther. 2020; 13:10707-10719. PMC: 7585791. DOI: 10.2147/OTT.S253730. View

Dome J, Fernandez C, Mullen E, Kalapurakal J, Geller J, Huff V . Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr Blood Cancer. 2012; 60(6):994-1000. PMC: 4127041. DOI: 10.1002/pbc.24419. View

Drake K, Ruteshouser E, Natrajan R, Harbor P, Wegert J, Gessler M . Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562. Clin Cancer Res. 2009; 15(19):5985-92. PMC: 2756455. DOI: 10.1158/1078-0432.CCR-09-1065. View

Han B, Chao J, Yao H . Circular RNA and its mechanisms in disease: From the bench to the clinic. Pharmacol Ther. 2018; 187:31-44. DOI: 10.1016/j.pharmthera.2018.01.010. View

Hansen T, Jensen T, Clausen B, Bramsen J, Finsen B, Damgaard C . Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495(7441):384-8. DOI: 10.1038/nature11993. View

10.

Hohenstein P, Pritchard-Jones K, Charlton J . The yin and yang of kidney development and Wilms' tumors. Genes Dev. 2015; 29(5):467-82. PMC: 4358399. DOI: 10.1101/gad.256396.114. View

11.

Hsiao K, Sun H, Tsai S . Circular RNA - New member of noncoding RNA with novel functions. Exp Biol Med (Maywood). 2017; 242(11):1136-1141. PMC: 5478007. DOI: 10.1177/1535370217708978. View

12.

Kanyamuhunga A, Tuyisenge L, Stefan D . Treating childhood cancer in Rwanda: the nephroblastoma example. Pan Afr Med J. 2015; 21:326. PMC: 4646289. DOI: 10.11604/pamj.2015.21.326.5912. View

13.

Li J, Luo P . MiR-140-5p and miR-92a-3p suppress the cell proliferation, migration and invasion and promoted apoptosis in Wilms' tumor by targeting FRS2. Eur Rev Med Pharmacol Sci. 2020; 24(1):97-108. DOI: 10.26355/eurrev_202001_19899. View

14.

Li T, Zhao P, Li Z, Wang C, Wang Y, Gu Q . miR-200c-3p Suppresses the Proliferative, Migratory, and Invasive Capacities of Nephroblastoma Cells via Targeting FRS2. Biopreserv Biobank. 2019; 17(5):444-451. DOI: 10.1089/bio.2019.0009. View

15.

Li R, Jiang J, Shi H, Qian H, Zhang X, Xu W . CircRNA: a rising star in gastric cancer. Cell Mol Life Sci. 2019; 77(9):1661-1680. PMC: 11104848. DOI: 10.1007/s00018-019-03345-5. View

16.

Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L . Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death Dis. 2019; 10(2):55. PMC: 6343010. DOI: 10.1038/s41419-018-1287-1. View

17.

Luo L, Kim E, Cheung H, Weir B, Dunn G, Shen R . The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res. 2014; 13(3):502-9. PMC: 4369154. DOI: 10.1158/1541-7786.MCR-14-0407. View

18.

Nie X, Su Z, Yan R, Yan A, Qiu S, Zhou Y . MicroRNA-562 negatively regulated c-MET/AKT pathway in the growth of glioblastoma cells. Onco Targets Ther. 2019; 12:41-49. PMC: 6306063. DOI: 10.2147/OTT.S186701. View

19.

Ren J, Huang H, Gong Y, Yue S, Tang L, Cheng S . MicroRNA-206 suppresses gastric cancer cell growth and metastasis. Cell Biosci. 2014; 4:26. PMC: 4030529. DOI: 10.1186/2045-3701-4-26. View

20.

Richards M, Goldin A, Savinkina A, Doski J, Goldfarb M, Nuchtern J . The association between nephroblastoma-specific outcomes and high versus low volume treatment centers. J Pediatr Surg. 2016; 52(1):104-108. DOI: 10.1016/j.jpedsurg.2016.10.029. View